patents.google.com

CN117924430B - TPOR-binding peptides that promote platelet production - Google Patents

  • ️Fri Jun 28 2024

CN117924430B - TPOR-binding peptides that promote platelet production - Google Patents

TPOR-binding peptides that promote platelet production Download PDF

Info

Publication number
CN117924430B
CN117924430B CN202410331263.4A CN202410331263A CN117924430B CN 117924430 B CN117924430 B CN 117924430B CN 202410331263 A CN202410331263 A CN 202410331263A CN 117924430 B CN117924430 B CN 117924430B Authority
CN
China
Prior art keywords
polypeptide
fusion protein
nucleic acid
radiation
acid molecule
Prior art date
2024-03-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202410331263.4A
Other languages
Chinese (zh)
Other versions
CN117924430A (en
Inventor
余祖胤
束慧
肖鹤
邢爽
申星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academy of Military Medical Sciences AMMS of PLA
Original Assignee
Academy of Military Medical Sciences AMMS of PLA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2024-03-22
Filing date
2024-03-22
Publication date
2024-06-28
2024-03-22 Application filed by Academy of Military Medical Sciences AMMS of PLA filed Critical Academy of Military Medical Sciences AMMS of PLA
2024-03-22 Priority to CN202410331263.4A priority Critical patent/CN117924430B/en
2024-04-26 Publication of CN117924430A publication Critical patent/CN117924430A/en
2024-06-28 Application granted granted Critical
2024-06-28 Publication of CN117924430B publication Critical patent/CN117924430B/en
Status Active legal-status Critical Current
2044-03-22 Anticipated expiration legal-status Critical

Links

  • 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 80
  • 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 72
  • 101000799466 Homo sapiens Thrombopoietin receptor Proteins 0.000 title claims abstract description 14
  • 102100034196 Thrombopoietin receptor Human genes 0.000 title claims abstract description 14
  • 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
  • 229920001184 polypeptide Polymers 0.000 claims abstract description 68
  • 102000037865 fusion proteins Human genes 0.000 claims abstract description 47
  • 108020001507 fusion proteins Proteins 0.000 claims abstract description 47
  • 108020004707 nucleic acids Proteins 0.000 claims abstract description 29
  • 102000039446 nucleic acids Human genes 0.000 claims abstract description 29
  • 150000007523 nucleic acids Chemical class 0.000 claims abstract description 29
  • 210000004027 cell Anatomy 0.000 claims abstract description 25
  • 210000003593 megakaryocyte Anatomy 0.000 claims abstract description 22
  • 239000013598 vector Substances 0.000 claims abstract description 20
  • 239000000203 mixture Substances 0.000 claims abstract description 16
  • 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
  • 238000002360 preparation method Methods 0.000 claims abstract description 8
  • 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
  • 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
  • 210000000601 blood cell Anatomy 0.000 claims abstract description 5
  • 230000005855 radiation Effects 0.000 claims description 18
  • 239000002773 nucleotide Substances 0.000 claims description 17
  • 125000003729 nucleotide group Chemical group 0.000 claims description 17
  • 206010028980 Neoplasm Diseases 0.000 claims description 14
  • 230000007812 deficiency Effects 0.000 claims description 11
  • 230000001154 acute effect Effects 0.000 claims description 7
  • 239000003814 drug Substances 0.000 claims description 7
  • 210000001519 tissue Anatomy 0.000 claims description 6
  • 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
  • 238000002512 chemotherapy Methods 0.000 claims description 4
  • 238000000338 in vitro Methods 0.000 claims description 4
  • 238000000034 method Methods 0.000 claims description 4
  • 238000001959 radiotherapy Methods 0.000 claims description 4
  • 208000011580 syndromic disease Diseases 0.000 claims description 4
  • 238000011282 treatment Methods 0.000 claims description 4
  • 230000001684 chronic effect Effects 0.000 claims description 2
  • 208000035475 disorder Diseases 0.000 claims description 2
  • 230000003449 preventive effect Effects 0.000 claims description 2
  • 230000000069 prophylactic effect Effects 0.000 claims description 2
  • 238000001356 surgical procedure Methods 0.000 claims description 2
  • 230000035899 viability Effects 0.000 claims description 2
  • 208000019155 Radiation injury Diseases 0.000 claims 3
  • 206010065553 Bone marrow failure Diseases 0.000 claims 1
  • 230000002265 prevention Effects 0.000 claims 1
  • 201000010099 disease Diseases 0.000 abstract description 11
  • 230000001737 promoting effect Effects 0.000 abstract description 6
  • 210000001772 blood platelet Anatomy 0.000 description 24
  • 102000036693 Thrombopoietin Human genes 0.000 description 14
  • 108010041111 Thrombopoietin Proteins 0.000 description 14
  • 241000699670 Mus sp. Species 0.000 description 12
  • 206010043554 thrombocytopenia Diseases 0.000 description 11
  • 230000006870 function Effects 0.000 description 9
  • 210000005259 peripheral blood Anatomy 0.000 description 9
  • 239000011886 peripheral blood Substances 0.000 description 9
  • 150000001413 amino acids Chemical class 0.000 description 8
  • 239000002904 solvent Substances 0.000 description 8
  • 238000002474 experimental method Methods 0.000 description 7
  • 230000014509 gene expression Effects 0.000 description 7
  • 210000000265 leukocyte Anatomy 0.000 description 7
  • 230000035921 thrombopoiesis Effects 0.000 description 7
  • 241000699666 Mus <mouse, genus> Species 0.000 description 6
  • 230000003247 decreasing effect Effects 0.000 description 6
  • 230000000694 effects Effects 0.000 description 6
  • 239000013612 plasmid Substances 0.000 description 6
  • 108090000623 proteins and genes Proteins 0.000 description 6
  • 238000011084 recovery Methods 0.000 description 6
  • 108020004414 DNA Proteins 0.000 description 5
  • 102000001554 Hemoglobins Human genes 0.000 description 5
  • 108010054147 Hemoglobins Proteins 0.000 description 5
  • 108091028043 Nucleic acid sequence Proteins 0.000 description 5
  • 239000002671 adjuvant Substances 0.000 description 5
  • 230000006378 damage Effects 0.000 description 5
  • 239000012634 fragment Substances 0.000 description 5
  • 230000004048 modification Effects 0.000 description 5
  • 238000012986 modification Methods 0.000 description 5
  • 239000000047 product Substances 0.000 description 5
  • 102000004169 proteins and genes Human genes 0.000 description 5
  • 238000002965 ELISA Methods 0.000 description 4
  • 210000001185 bone marrow Anatomy 0.000 description 4
  • 201000011510 cancer Diseases 0.000 description 4
  • 238000001514 detection method Methods 0.000 description 4
  • 210000003743 erythrocyte Anatomy 0.000 description 4
  • 230000002093 peripheral effect Effects 0.000 description 4
  • 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
  • 210000004369 blood Anatomy 0.000 description 3
  • 239000008280 blood Substances 0.000 description 3
  • 230000008859 change Effects 0.000 description 3
  • KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
  • UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
  • 239000000539 dimer Substances 0.000 description 3
  • 229940079593 drug Drugs 0.000 description 3
  • 210000004976 peripheral blood cell Anatomy 0.000 description 3
  • 238000000746 purification Methods 0.000 description 3
  • 230000001105 regulatory effect Effects 0.000 description 3
  • 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
  • 239000000243 solution Substances 0.000 description 3
  • 238000006467 substitution reaction Methods 0.000 description 3
  • 239000003053 toxin Substances 0.000 description 3
  • 231100000765 toxin Toxicity 0.000 description 3
  • 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
  • 241000283707 Capra Species 0.000 description 2
  • 108091026890 Coding region Proteins 0.000 description 2
  • 108020004705 Codon Proteins 0.000 description 2
  • 102000004127 Cytokines Human genes 0.000 description 2
  • 108090000695 Cytokines Proteins 0.000 description 2
  • 102000053602 DNA Human genes 0.000 description 2
  • 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 2
  • 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 description 2
  • 108060003951 Immunoglobulin Proteins 0.000 description 2
  • 108010076504 Protein Sorting Signals Proteins 0.000 description 2
  • QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
  • 208000027276 Von Willebrand disease Diseases 0.000 description 2
  • 208000027418 Wounds and injury Diseases 0.000 description 2
  • 230000002159 abnormal effect Effects 0.000 description 2
  • 230000005856 abnormality Effects 0.000 description 2
  • 238000002835 absorbance Methods 0.000 description 2
  • 230000000903 blocking effect Effects 0.000 description 2
  • 238000004820 blood count Methods 0.000 description 2
  • 239000000872 buffer Substances 0.000 description 2
  • 238000006243 chemical reaction Methods 0.000 description 2
  • 238000001962 electrophoresis Methods 0.000 description 2
  • 239000013604 expression vector Substances 0.000 description 2
  • 210000001035 gastrointestinal tract Anatomy 0.000 description 2
  • 230000013595 glycosylation Effects 0.000 description 2
  • 238000006206 glycosylation reaction Methods 0.000 description 2
  • 201000009277 hairy cell leukemia Diseases 0.000 description 2
  • 102000053400 human TPO Human genes 0.000 description 2
  • 102000018358 immunoglobulin Human genes 0.000 description 2
  • 230000006872 improvement Effects 0.000 description 2
  • 208000014674 injury Diseases 0.000 description 2
  • 238000003780 insertion Methods 0.000 description 2
  • 230000037431 insertion Effects 0.000 description 2
  • 210000004185 liver Anatomy 0.000 description 2
  • 201000007270 liver cancer Diseases 0.000 description 2
  • 208000014018 liver neoplasm Diseases 0.000 description 2
  • 239000002504 physiological saline solution Substances 0.000 description 2
  • 108091033319 polynucleotide Proteins 0.000 description 2
  • 102000040430 polynucleotide Human genes 0.000 description 2
  • 239000002157 polynucleotide Substances 0.000 description 2
  • 108020003175 receptors Proteins 0.000 description 2
  • 102000005962 receptors Human genes 0.000 description 2
  • 238000012163 sequencing technique Methods 0.000 description 2
  • 230000001629 suppression Effects 0.000 description 2
  • 238000012360 testing method Methods 0.000 description 2
  • 239000013638 trimer Substances 0.000 description 2
  • 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 2
  • GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
  • 208000030507 AIDS Diseases 0.000 description 1
  • 208000010400 APUDoma Diseases 0.000 description 1
  • 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
  • 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
  • 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
  • 208000003200 Adenoma Diseases 0.000 description 1
  • 206010001233 Adenoma benign Diseases 0.000 description 1
  • 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
  • 208000032467 Aplastic anaemia Diseases 0.000 description 1
  • 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
  • 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
  • 241000894006 Bacteria Species 0.000 description 1
  • 206010005003 Bladder cancer Diseases 0.000 description 1
  • 241000283690 Bos taurus Species 0.000 description 1
  • 208000003174 Brain Neoplasms Diseases 0.000 description 1
  • 206010006187 Breast cancer Diseases 0.000 description 1
  • 208000026310 Breast neoplasm Diseases 0.000 description 1
  • 206010007270 Carcinoid syndrome Diseases 0.000 description 1
  • 241000700199 Cavia porcellus Species 0.000 description 1
  • 208000007389 Cementoma Diseases 0.000 description 1
  • 206010008342 Cervix carcinoma Diseases 0.000 description 1
  • 208000005243 Chondrosarcoma Diseases 0.000 description 1
  • 201000009047 Chordoma Diseases 0.000 description 1
  • 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
  • 206010009944 Colon cancer Diseases 0.000 description 1
  • 241000699800 Cricetinae Species 0.000 description 1
  • 238000011238 DNA vaccination Methods 0.000 description 1
  • 241000702421 Dependoparvovirus Species 0.000 description 1
  • 238000012286 ELISA Assay Methods 0.000 description 1
  • 241000196324 Embryophyta Species 0.000 description 1
  • 206010014733 Endometrial cancer Diseases 0.000 description 1
  • 206010014759 Endometrial neoplasm Diseases 0.000 description 1
  • 241000283073 Equus caballus Species 0.000 description 1
  • 241000588724 Escherichia coli Species 0.000 description 1
  • 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
  • 208000006168 Ewing Sarcoma Diseases 0.000 description 1
  • 208000026019 Fanconi renotubular syndrome Diseases 0.000 description 1
  • 201000006328 Fanconi syndrome Diseases 0.000 description 1
  • 102000009109 Fc receptors Human genes 0.000 description 1
  • 108010087819 Fc receptors Proteins 0.000 description 1
  • 108010008177 Fd immunoglobulins Proteins 0.000 description 1
  • 241000282326 Felis catus Species 0.000 description 1
  • 201000008808 Fibrosarcoma Diseases 0.000 description 1
  • 206010016880 Folate deficiency Diseases 0.000 description 1
  • 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
  • 241000233866 Fungi Species 0.000 description 1
  • 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
  • 208000007569 Giant Cell Tumors Diseases 0.000 description 1
  • 208000032612 Glial tumor Diseases 0.000 description 1
  • 206010018338 Glioma Diseases 0.000 description 1
  • 102000003886 Glycoproteins Human genes 0.000 description 1
  • 108090000288 Glycoproteins Proteins 0.000 description 1
  • 208000031886 HIV Infections Diseases 0.000 description 1
  • 208000037357 HIV infectious disease Diseases 0.000 description 1
  • 208000002927 Hamartoma Diseases 0.000 description 1
  • 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
  • 241000238631 Hexapoda Species 0.000 description 1
  • 208000017604 Hodgkin disease Diseases 0.000 description 1
  • 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
  • 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
  • 241000282412 Homo Species 0.000 description 1
  • 201000002980 Hyperparathyroidism Diseases 0.000 description 1
  • 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
  • 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
  • 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
  • 208000007766 Kaposi sarcoma Diseases 0.000 description 1
  • 208000008839 Kidney Neoplasms Diseases 0.000 description 1
  • 241000713666 Lentivirus Species 0.000 description 1
  • 206010024612 Lipoma Diseases 0.000 description 1
  • 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
  • 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
  • 208000008095 Malignant Carcinoid Syndrome Diseases 0.000 description 1
  • 206010026673 Malignant Pleural Effusion Diseases 0.000 description 1
  • 208000032271 Malignant tumor of penis Diseases 0.000 description 1
  • 241000124008 Mammalia Species 0.000 description 1
  • 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 1
  • 208000010153 Mesonephroma Diseases 0.000 description 1
  • 206010027406 Mesothelioma Diseases 0.000 description 1
  • 208000034578 Multiple myelomas Diseases 0.000 description 1
  • 241001529936 Murinae Species 0.000 description 1
  • 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
  • 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
  • 208000005927 Myosarcoma Diseases 0.000 description 1
  • 206010029260 Neuroblastoma Diseases 0.000 description 1
  • 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
  • 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
  • 108091034117 Oligonucleotide Proteins 0.000 description 1
  • 241000283973 Oryctolagus cuniculus Species 0.000 description 1
  • 206010033128 Ovarian cancer Diseases 0.000 description 1
  • 206010061535 Ovarian neoplasm Diseases 0.000 description 1
  • 101150030083 PE38 gene Proteins 0.000 description 1
  • 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
  • 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
  • 241001494479 Pecora Species 0.000 description 1
  • 208000002471 Penile Neoplasms Diseases 0.000 description 1
  • 206010034299 Penile cancer Diseases 0.000 description 1
  • 241000009328 Perro Species 0.000 description 1
  • 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
  • 206010035226 Plasma cell myeloma Diseases 0.000 description 1
  • 208000007452 Plasmacytoma Diseases 0.000 description 1
  • 208000013544 Platelet disease Diseases 0.000 description 1
  • 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
  • 206010060862 Prostate cancer Diseases 0.000 description 1
  • 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
  • 241000589516 Pseudomonas Species 0.000 description 1
  • 241000700159 Rattus Species 0.000 description 1
  • 108020004511 Recombinant DNA Proteins 0.000 description 1
  • 206010038389 Renal cancer Diseases 0.000 description 1
  • 206010038802 Reticuloendothelial system stimulated Diseases 0.000 description 1
  • 201000000582 Retinoblastoma Diseases 0.000 description 1
  • 108010039491 Ricin Proteins 0.000 description 1
  • 241000283984 Rodentia Species 0.000 description 1
  • 241000235070 Saccharomyces Species 0.000 description 1
  • 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
  • 206010039491 Sarcoma Diseases 0.000 description 1
  • 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
  • 208000000453 Skin Neoplasms Diseases 0.000 description 1
  • 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
  • 206010041660 Splenomegaly Diseases 0.000 description 1
  • 208000005718 Stomach Neoplasms Diseases 0.000 description 1
  • 241000282898 Sus scrofa Species 0.000 description 1
  • 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
  • 206010043276 Teratoma Diseases 0.000 description 1
  • 208000024313 Testicular Neoplasms Diseases 0.000 description 1
  • 206010057644 Testis cancer Diseases 0.000 description 1
  • 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
  • 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
  • 208000024770 Thyroid neoplasm Diseases 0.000 description 1
  • 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
  • 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
  • 208000002495 Uterine Neoplasms Diseases 0.000 description 1
  • 206010046798 Uterine leiomyoma Diseases 0.000 description 1
  • 206010047741 Vulval cancer Diseases 0.000 description 1
  • 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
  • 208000008383 Wilms tumor Diseases 0.000 description 1
  • 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 description 1
  • JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
  • 239000003070 absorption delaying agent Substances 0.000 description 1
  • 230000021736 acetylation Effects 0.000 description 1
  • 238000006640 acetylation reaction Methods 0.000 description 1
  • 229910052767 actinium Inorganic materials 0.000 description 1
  • QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 1
  • 230000009471 action Effects 0.000 description 1
  • 239000012190 activator Substances 0.000 description 1
  • 239000004480 active ingredient Substances 0.000 description 1
  • 239000013543 active substance Substances 0.000 description 1
  • 201000002454 adrenal cortex cancer Diseases 0.000 description 1
  • 125000000539 amino acid group Chemical class 0.000 description 1
  • 239000003242 anti bacterial agent Substances 0.000 description 1
  • 230000000844 anti-bacterial effect Effects 0.000 description 1
  • 230000000692 anti-sense effect Effects 0.000 description 1
  • 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
  • 239000003429 antifungal agent Substances 0.000 description 1
  • 229940121375 antifungal agent Drugs 0.000 description 1
  • 239000000427 antigen Substances 0.000 description 1
  • 102000036639 antigens Human genes 0.000 description 1
  • 108091007433 antigens Proteins 0.000 description 1
  • 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
  • 210000003578 bacterial chromosome Anatomy 0.000 description 1
  • 230000001580 bacterial effect Effects 0.000 description 1
  • 230000009286 beneficial effect Effects 0.000 description 1
  • 230000008901 benefit Effects 0.000 description 1
  • 239000011230 binding agent Substances 0.000 description 1
  • 230000004071 biological effect Effects 0.000 description 1
  • 230000008827 biological function Effects 0.000 description 1
  • 239000012620 biological material Substances 0.000 description 1
  • 229910052797 bismuth Inorganic materials 0.000 description 1
  • JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
  • 230000017531 blood circulation Effects 0.000 description 1
  • 238000010241 blood sampling Methods 0.000 description 1
  • 238000006664 bond formation reaction Methods 0.000 description 1
  • 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
  • -1 but not limited to Chemical compound 0.000 description 1
  • 238000004364 calculation method Methods 0.000 description 1
  • 208000005761 carcinoid heart disease Diseases 0.000 description 1
  • 210000000845 cartilage Anatomy 0.000 description 1
  • 238000004113 cell culture Methods 0.000 description 1
  • 201000010881 cervical cancer Diseases 0.000 description 1
  • 239000003153 chemical reaction reagent Substances 0.000 description 1
  • 239000003795 chemical substances by application Substances 0.000 description 1
  • 201000005217 chondroblastoma Diseases 0.000 description 1
  • 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
  • 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
  • 239000011248 coating agent Substances 0.000 description 1
  • 238000000576 coating method Methods 0.000 description 1
  • 208000029742 colonic neoplasm Diseases 0.000 description 1
  • 230000000295 complement effect Effects 0.000 description 1
  • 238000012790 confirmation Methods 0.000 description 1
  • 238000010276 construction Methods 0.000 description 1
  • 230000001276 controlling effect Effects 0.000 description 1
  • 239000012228 culture supernatant Substances 0.000 description 1
  • 210000004748 cultured cell Anatomy 0.000 description 1
  • 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
  • 230000001086 cytosolic effect Effects 0.000 description 1
  • 238000012217 deletion Methods 0.000 description 1
  • 230000037430 deletion Effects 0.000 description 1
  • 238000010586 diagram Methods 0.000 description 1
  • 230000004069 differentiation Effects 0.000 description 1
  • 230000029087 digestion Effects 0.000 description 1
  • 239000007884 disintegrant Substances 0.000 description 1
  • 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
  • 239000003995 emulsifying agent Substances 0.000 description 1
  • 239000002158 endotoxin Substances 0.000 description 1
  • 238000005516 engineering process Methods 0.000 description 1
  • 239000003623 enhancer Substances 0.000 description 1
  • 230000002708 enhancing effect Effects 0.000 description 1
  • 238000001976 enzyme digestion Methods 0.000 description 1
  • 201000004101 esophageal cancer Diseases 0.000 description 1
  • 239000013613 expression plasmid Substances 0.000 description 1
  • 239000000945 filler Substances 0.000 description 1
  • 238000001914 filtration Methods 0.000 description 1
  • 201000010175 gallbladder cancer Diseases 0.000 description 1
  • 230000005251 gamma ray Effects 0.000 description 1
  • 206010017758 gastric cancer Diseases 0.000 description 1
  • 230000030279 gene silencing Effects 0.000 description 1
  • 210000004602 germ cell Anatomy 0.000 description 1
  • 208000014829 head and neck neoplasm Diseases 0.000 description 1
  • 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
  • 239000000833 heterodimer Substances 0.000 description 1
  • 239000000710 homodimer Substances 0.000 description 1
  • 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
  • 210000002865 immune cell Anatomy 0.000 description 1
  • 230000032226 immune complex clearance Effects 0.000 description 1
  • 230000006058 immune tolerance Effects 0.000 description 1
  • 230000036039 immunity Effects 0.000 description 1
  • 230000005847 immunogenicity Effects 0.000 description 1
  • 229940072221 immunoglobulins Drugs 0.000 description 1
  • 238000001727 in vivo Methods 0.000 description 1
  • 230000001939 inductive effect Effects 0.000 description 1
  • 230000028709 inflammatory response Effects 0.000 description 1
  • 230000000977 initiatory effect Effects 0.000 description 1
  • 230000003993 interaction Effects 0.000 description 1
  • 230000000968 intestinal effect Effects 0.000 description 1
  • PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
  • 239000007951 isotonicity adjuster Substances 0.000 description 1
  • 210000003734 kidney Anatomy 0.000 description 1
  • 201000010982 kidney cancer Diseases 0.000 description 1
  • 201000010260 leiomyoma Diseases 0.000 description 1
  • 150000002632 lipids Chemical class 0.000 description 1
  • 206010024627 liposarcoma Diseases 0.000 description 1
  • 208000019423 liver disease Diseases 0.000 description 1
  • 239000000314 lubricant Substances 0.000 description 1
  • 210000004072 lung Anatomy 0.000 description 1
  • 201000005202 lung cancer Diseases 0.000 description 1
  • 210000005265 lung cell Anatomy 0.000 description 1
  • 208000020816 lung neoplasm Diseases 0.000 description 1
  • 230000003211 malignant effect Effects 0.000 description 1
  • 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
  • 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
  • 208000026037 malignant tumor of neck Diseases 0.000 description 1
  • 210000004962 mammalian cell Anatomy 0.000 description 1
  • 230000035800 maturation Effects 0.000 description 1
  • 201000001441 melanoma Diseases 0.000 description 1
  • 239000012528 membrane Substances 0.000 description 1
  • 208000011831 mesonephric neoplasm Diseases 0.000 description 1
  • 206010061289 metastatic neoplasm Diseases 0.000 description 1
  • 244000005700 microbiome Species 0.000 description 1
  • 239000008267 milk Substances 0.000 description 1
  • 210000004080 milk Anatomy 0.000 description 1
  • 235000013336 milk Nutrition 0.000 description 1
  • 239000000178 monomer Substances 0.000 description 1
  • 201000002077 muscle cancer Diseases 0.000 description 1
  • 201000005962 mycosis fungoides Diseases 0.000 description 1
  • 208000009091 myxoma Diseases 0.000 description 1
  • 208000001611 myxosarcoma Diseases 0.000 description 1
  • 230000003472 neutralizing effect Effects 0.000 description 1
  • 210000004940 nucleus Anatomy 0.000 description 1
  • 210000000056 organ Anatomy 0.000 description 1
  • 208000008798 osteoma Diseases 0.000 description 1
  • 201000008968 osteosarcoma Diseases 0.000 description 1
  • 230000002611 ovarian Effects 0.000 description 1
  • 201000002528 pancreatic cancer Diseases 0.000 description 1
  • 208000008443 pancreatic carcinoma Diseases 0.000 description 1
  • 208000003154 papilloma Diseases 0.000 description 1
  • 210000004738 parenchymal cell Anatomy 0.000 description 1
  • 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
  • 230000026731 phosphorylation Effects 0.000 description 1
  • 238000006366 phosphorylation reaction Methods 0.000 description 1
  • 239000013600 plasmid vector Substances 0.000 description 1
  • 230000008488 polyadenylation Effects 0.000 description 1
  • 229920000642 polymer Polymers 0.000 description 1
  • 230000004481 post-translational protein modification Effects 0.000 description 1
  • 239000002243 precursor Substances 0.000 description 1
  • 239000003755 preservative agent Substances 0.000 description 1
  • 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
  • 238000012545 processing Methods 0.000 description 1
  • 230000035755 proliferation Effects 0.000 description 1
  • 238000003259 recombinant expression Methods 0.000 description 1
  • 230000009467 reduction Effects 0.000 description 1
  • 201000000849 skin cancer Diseases 0.000 description 1
  • 125000006850 spacer group Chemical group 0.000 description 1
  • 206010041823 squamous cell carcinoma Diseases 0.000 description 1
  • 238000010561 standard procedure Methods 0.000 description 1
  • 230000001954 sterilising effect Effects 0.000 description 1
  • 238000004659 sterilization and disinfection Methods 0.000 description 1
  • 230000004936 stimulating effect Effects 0.000 description 1
  • 201000011549 stomach cancer Diseases 0.000 description 1
  • 238000003860 storage Methods 0.000 description 1
  • 239000000375 suspending agent Substances 0.000 description 1
  • 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
  • 201000003120 testicular cancer Diseases 0.000 description 1
  • 238000002560 therapeutic procedure Methods 0.000 description 1
  • 208000008732 thymoma Diseases 0.000 description 1
  • 201000002510 thyroid cancer Diseases 0.000 description 1
  • 231100000331 toxic Toxicity 0.000 description 1
  • 230000002588 toxic effect Effects 0.000 description 1
  • 230000001988 toxicity Effects 0.000 description 1
  • 231100000419 toxicity Toxicity 0.000 description 1
  • 230000002103 transcriptional effect Effects 0.000 description 1
  • 238000001890 transfection Methods 0.000 description 1
  • 238000011426 transformation method Methods 0.000 description 1
  • 238000013519 translation Methods 0.000 description 1
  • 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
  • 241000701161 unidentified adenovirus Species 0.000 description 1
  • 201000005112 urinary bladder cancer Diseases 0.000 description 1
  • 206010046766 uterine cancer Diseases 0.000 description 1
  • 206010046885 vaginal cancer Diseases 0.000 description 1
  • 208000013139 vaginal neoplasm Diseases 0.000 description 1
  • 210000003462 vein Anatomy 0.000 description 1
  • 239000013603 viral vector Substances 0.000 description 1
  • 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
  • 201000005102 vulva cancer Diseases 0.000 description 1
  • 239000000080 wetting agent Substances 0.000 description 1
  • 229910052727 yttrium Inorganic materials 0.000 description 1
  • VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了促进血小板生成的TPOR结合肽，本发明提供了一种具有治疗功能的多肽，以及包含多肽的融合蛋白，本发明还提供了能够编码前述多肽及融合蛋白的核酸分子以及载体，本发明还提供了包含前述多肽、融合蛋白、核酸分子、载体的组合物，本发明还提供了前述多肽、融合蛋白、核酸分子、载体、组合物在提升个体血细胞生产数量的药物组合物中的应用及治疗血小板数量不足导致疾病的药物组合物中的应用，本发明还提供了前述多肽及融合蛋白在制备检测给个体TPOR水平的产品中的应用，本发明还提供了前述多肽及融合蛋白在制备用于维持血小板和/或巨核细胞相关细胞的活力的产品中的应用。

The present invention discloses a TPOR-binding peptide for promoting platelet production. The present invention provides a polypeptide with therapeutic function, and a fusion protein comprising the polypeptide. The present invention also provides a nucleic acid molecule and a vector capable of encoding the aforementioned polypeptide and fusion protein. The present invention also provides a composition comprising the aforementioned polypeptide, fusion protein, nucleic acid molecule, and vector. The present invention also provides the use of the aforementioned polypeptide, fusion protein, nucleic acid molecule, vector, and composition in a pharmaceutical composition for increasing the number of blood cells produced by an individual and in a pharmaceutical composition for treating diseases caused by insufficient platelet count. The present invention also provides the use of the aforementioned polypeptide and fusion protein in the preparation of a product for detecting the TPOR level of an individual. The present invention also provides the use of the aforementioned polypeptide and fusion protein in the preparation of a product for maintaining the vitality of platelet and/or megakaryocyte-related cells.

Description

TPOR binding peptides that promote thrombopoiesis

Technical Field

The invention belongs to the technical field of biology, and relates to TPOR binding peptides for promoting thrombopoiesis.

Background

Thrombopoietin (TPO) is the most important cytokine in the human body that promotes thrombopoiesis. TPO exerts a platelet-producing promoting effect by binding to the cell surface TPO receptor (TPO-R). Thrombopoietin (TPO) is a signal peptide which is mainly synthesized and secreted by the liver and released to the blood circulation, has the effects of regulating megakaryocyte maturation and promoting thrombopoiesis, and is the most important cytokine for promoting thrombopoiesis in the body. At present, the platelet-promoting medicament widely applied clinically is recombinant human TPO (recombinant human TPO, rh-TPO), but the medicament has the problems of inconvenient administration route and shorter effective time, so that more convenient and effective platelet-promoting medicaments are urgently required to be searched.

Disclosure of Invention

In order to solve the technical problems in the prior art, the invention provides the following technical scheme:

the invention provides a polypeptide with a therapeutic or preventive function, and the amino acid sequence of the polypeptide is shown as SEQ ID NO. 1.

In some embodiments, the polypeptide is a TPOR-binding peptide, in particular embodiments, the polypeptide promotes thrombopoiesis by binding to TPOR. In a specific embodiment, the therapeutic function of the polypeptide refers to a platelet production promoting function. In a specific embodiment, the polypeptide is an analog of TPO that has the biological function of TPO.

The term "TPO" refers to thrombopoietin (thrombopoetin), a physiologically significant thrombopoietin regulator, and TPO is produced primarily in liver parenchymal cells in much smaller amounts in the kidneys and bone marrow, and in vivo synthesized TPO is a precursor protein containing 353 amino acids and has a molecular weight of 36kDa, with the remaining 332 amino acids being glycosylated to form a 95kDa glycoprotein after removal of the 21 amino acid signal peptide. The term "TPOR" refers to TPO receptor, which has the functions of regulating HSC proliferation and differentiation and expansion of multipotent hematopoietic progenitor cells, and also has the functions of regulating immunity and inducing immune tolerance.

In some embodiments, the polypeptides further comprise different linkers. In some embodiments, what groups the linker belongs to is optional. In some embodiments, when a linker is present, its specific structure is not critical, primarily whether the linker functions as a spacer. In some specific embodiments, the linker is preferably composed of amino acids linked by peptide bonds. In some preferred embodiments, the linker is comprised of 1-50 amino acids connected by peptide bonds, said amino acids being selected from 20 natural amino acids. In some preferred embodiments, the amino acids used in the linker may be single or multiple glycosylated. In some embodiments, the linker may be a non-peptide linker, such as an alkyl linker.

The term "polypeptide" describes a population of such molecules: the population of molecules comprises a group of peptides consisting of at least 2 amino acids. The term "polypeptide" also includes proteins and protein fragments. Polypeptides may form dimers, trimers and higher oligomers, i.e. consist of more than one polypeptide molecule. The polypeptide molecules forming such dimers, trimers, etc. may be the same or different. Accordingly, the corresponding higher order structure is named homodimer or heterodimer, homotrimer or heterotrimer, etc. Homodimers, heterodimers, and the like also fall within the definition of the term "polypeptide". The terms "polypeptide" and "protein" are used interchangeably herein. The term "polypeptide" also refers to naturally modified polypeptides, wherein the modification is accomplished, for example, by post-translational modifications (e.g., glycosylation, acetylation, and phosphorylation, etc.). Such modifications are well known in the art.

The invention provides a fusion protein with therapeutic or prophylactic function, which comprises the polypeptide.

Further, the aforementioned polypeptide is linked to the Fc region of an antibody.

Further, the amino acid sequence of the Fc region is shown in SEQ ID NO. 3.

In some embodiments, the Fc region of the antibody is a native Fc, meaning a molecule or sequence comprising a non-antigen binding fragment sequence, whether in monomeric or multimeric form, produced by digestion of an intact antibody, to which a peptide sequence may be added by insertion and substitution of loop regions. In some embodiments, the source of the original antibody of the native Fc is preferably human, and may preferably be any of the immunoglobulins, the classes including IgG, igM, igA, igD and IgE. In some embodiments, the immunoglobulin class is preferably IgG, more preferably IgG1. In some embodiments, the native Fc is comprised of monomeric polypeptides that can be linked as dimers or multimers by covalent and non-covalent linkages. In some embodiments, the number of intermolecular disulfide bonds between the individual monomer subunits of the native Fc molecule depends on classes or subclasses, including, but not limited to IgG, igM, igA, igD and IgE, including, but not limited to IgG1, igG2, igG3, igA1, igGA2.

In some embodiments, the Fc region of the antibody is an Fc variant, meaning a native Fc modified molecule or sequence that still includes sites for binding Fc receptors on the surface of immune cells, still is capable of mediating ADCC and ADCP, and still may be involved in immune complex clearance, modulating inflammatory response, and delivering a drug. In some embodiments, the Fc variant comprises a molecule or sequence humanized from a non-human native Fc. In some embodiments, the Fc variants include molecules or sequences lacking single or multiple native Fc sites or residues that affect or participate in the following actions: disulfide bond formation, incompatibility with the cell of interest, N-terminal heterogeneity upon cell expression, glycosylation, interaction with complement, antibody Dependent Cellular Cytotoxicity (ADCC).

Further, the aforementioned polypeptide has a linker between the polypeptide and the Fc region of the antibody.

Further, the amino acid sequence of the linker is shown as SEQ ID NO. 2.

Further, the polypeptide described above is integrated into: a hinge region of a heavy chain polypeptide, a junction between a hinge region and other portions, or a constant region of a light chain polypeptide.

Further, the fusion protein comprises a single or a plurality of the polypeptides described above.

Further, the fusion protein includes a native or recombinant heavy chain polypeptide, a light chain polypeptide, or a combination thereof.

Further, the antibodies include monoclonal antibodies, bispecific antibodies, single chain antibodies, nanobodies, fd fragments, fab 'fragments or F (ab') 2 fragments, fc fragments.

Further, the antibodies include IgG, igM, igA, igD and IgE.

In some specific embodiments, the fusion protein is formed by ligating the polypeptides, linkers and Fc regions of antibodies as described above, in sequence, with the specific fusion protein sequences shown in SEQ ID NO. 7.

In some embodiments, the polypeptides described above or the fusion proteins described above further comprise corresponding derivatives including modified molecules other than insertion, deletion or substitution of amino acid residues. In some embodiments, the modifications in the derivatives are covalent in nature, specific examples of the derivatives include, but are not limited to, chemically bound polymers, lipids, other organic and inorganic moieties. In some embodiments, the purpose of the derivative preparation includes improving the circulatory half-life of the molecule, improving the ability of the molecule to target a cell, tissue, or organ of interest, improving the solubility or absorbability of the molecule, and eliminating or reducing side effects of the molecule.

In some embodiments, the derivative comprises a conjugated derivative of an isotope or toxin to a polypeptide as described above or a fusion protein as described above. In some specific embodiments, the class of conjugated derivatives includes toxin-derivatives, tracer-derivatives, radioisotope-derivatives.

In some embodiments, the radioisotope includes, but is not limited to, 90 yttrium, 131 iodine, 225 actinium, and 213 bismuth, including, but not limited to, ricin a toxin, a microorganism-derived toxin such as pseudomonas endotoxin (e.g., PE38, PE 40), and the like.

The present invention provides a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide as described above or a fusion protein as described above.

Further, the nucleotide sequence encoding the polypeptide as described above has at least 90% sequence identity, preferably at least 95% sequence identity, preferably at least 96% sequence identity, preferably at least 97% sequence identity, preferably at least 98% sequence identity, preferably at least 99% sequence identity, preferably at least 100% sequence identity to the nucleotide sequence of SEQ ID NO. 4.

Further, the nucleotide sequence of the nucleic acid molecule encoding the polypeptide is shown as SEQ ID NO. 4.

Further, the nucleic acid molecule also comprises a nucleotide sequence encoding an Fc region of an antibody, said Fc region having at least 90% sequence identity, preferably at least 95% sequence identity, preferably at least 96% sequence identity, preferably at least 97% sequence identity, preferably at least 98% sequence identity, preferably at least 99% sequence identity, preferably at least 100% sequence identity to the nucleotide sequence shown in SEQ ID NO. 6.

Further, the nucleotide sequence of the Fc region is shown in SEQ ID NO. 6.

Further, the nucleic acid molecule also includes a nucleotide sequence encoding a linker that links the polypeptide described above to the Fc region of an antibody.

Further, the nucleotide sequence encoding the linker includes the nucleotide sequence shown as SEQ ID NO. 5.

In some embodiments, the nucleic acid molecule may be optimized by a change at the DNA level. In some embodiments, the step of optimizing the nucleic acid molecule comprises altering the DNA sequence to render the nucleic acid molecule more compatible with the selected host cell. In some more specific embodiments, the change in the DNA sequence of the nucleic acid molecule is a change in accordance with codon degeneracy. In some embodiments, the substitutions can be made in the nucleic acid molecule according to codon degeneracy to eliminate restriction sites or silencing sites, allowing for smoother processing, translation of the nucleic acid molecule in the cell of interest.

In some embodiments, the sequence identity refers to comparing two optimally aligned sequences based on the comparison window being the same, the number of positions in the two sequences where the same sequence unit occurs to obtain the number of matching positions, and dividing the number of matching positions by the total number of positions in the comparison window to obtain the result of the calculation.

Further, the nucleotide sequence encoding the fusion protein has at least 90% sequence identity, preferably at least 95% sequence identity, preferably at least 96% sequence identity, preferably at least 97% sequence identity, preferably at least 98% sequence identity, preferably at least 99% sequence identity, preferably at least 100% sequence identity to the nucleotide sequence shown in SEQ ID NO. 8.

Further, the nucleotide sequence of the encoding fusion protein is shown as SEQ ID NO. 8.

The terms "nucleic acid", "nucleic acid molecule", "nucleic acid sequence", "nucleotide sequence", "polynucleotide sequence", "RNA sequence" or "DNA sequence" refer to oligonucleotides, nucleotides or polynucleotides and fragments and portions thereof and refer to DNA or RNA of genomic or synthetic origin, which may be single-stranded or double-stranded and represent the sense or antisense strand. The sequence may be a non-coding sequence, a coding sequence, or a mixture of both. The nucleic acid molecules used in the present invention may be prepared by standard techniques well known to those skilled in the art.

In some specific embodiments, the nucleotide sequence encoding the fusion protein is set forth in SEQ ID NO. 8.

The present invention provides a vector comprising a nucleic acid molecule as described above.

Further, the vector includes a plasmid, a lentivirus, an adenovirus, an adeno-associated virus, and a transposon vector.

In some embodiments, the vector is a vector capable of expressing the polypeptide or fusion protein in a suitable cell, tissue. In some embodiments, the vector comprises a nucleic acid molecule encoding the polypeptide or fusion protein described above, including a DNA molecule or an RNA molecule, operably linked to a suitable expression sequence. In some embodiments, the vector comprises, in addition to a nucleic acid molecule encoding the polypeptide or fusion protein described above, sequences capable of controlling expression, including promoters, activators, enhancers, operators, ribosome binding sites, initiation signals, termination signals, capping signals, polyadenylation signals, and other signals involved in transcriptional or translational control.

In some embodiments, the vector is used to transform into a host cell, which is well known to those skilled in the art, and the transformation methods are also well known to those skilled in the art. In some embodiments, the choice of the host cell depends on a variety of factors recognized in the art, including compatibility with the selected expression vector, toxicity of the peptide encoded by the DNA molecule, conversion rate, ease of recovery of the peptide, expression profile, biosafety, and cost. In some embodiments, the host cells are not equally effective in expressing the polypeptides, fusion proteins, nucleic acid molecules or vectors of the invention, and this understanding must be balanced between these factors. In some specific embodiments, the host cells include cultured cells of bacteria (e.g., E.coli species), yeast (e.g., saccharomyces species), and other fungi, insects, plants, mammals (including humans), or other hosts known in the art.

The term "plasmid" refers to cytoplasmic DNA that replicates in a bacterial host cell independently of the bacterial chromosome. In the specific description of the present invention, the term "plasmid" or "plasmid vector" refers to an element of recombinant DNA technology that can be used to construct an expression cassette inserted into a viral vector. In addition, the term "plasmid" may also be used to refer to a plasmid suitable for DNA vaccination purposes.

The present invention provides a composition comprising a polypeptide as described above, a fusion protein as described above, a nucleic acid molecule as described above, a vector as described above.

Further, the composition may further comprise pharmaceutically acceptable adjuvants.

In some embodiments, a pharmaceutically acceptable adjuvant of the composition refers to an agent capable of imparting or enhancing stability, delivery, appearance, or feel in use to the composition. In some embodiments, the adjuvant must be well tolerated by the subject. In some more specific embodiments, the use of the adjuvant in a proteinaceous composition should take into account the efficacy or immunogenicity of the composition during use or storage.

The term "pharmaceutically acceptable adjuvant" refers to a component that does not interfere with the efficacy of the biological activity of the active ingredient and that is not significantly toxic to the host at the concentrations at which it is applied, including solvents, fillers, wetting agents, binders, disintegrants, lubricants, preservatives, suspending agents, emulsifying agents, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such components for pharmaceutically active substances is well known in the art.

The invention provides the application of the polypeptide, the fusion protein, the nucleic acid molecule, the vector and the composition in preparation of pharmaceutical compositions for improving the production quantity of individual blood cells.

Further, the individual includes a human or non-human mammal.

In some embodiments, the subject includes human, non-human primate, cat, dog, sheep, goat, cow, horse, pig, rabbit, rodent cells including mouse, hamster, rat, and guinea pig, as well as any derivatives and offspring thereof.

Further, the blood cells include white blood cells, red blood cells, platelets, hemoglobin.

The invention provides application of the polypeptide, the fusion protein, the nucleic acid molecule, the vector and the composition in preparing a pharmaceutical composition for treating or preventing diseases caused by insufficient platelet number.

Further, the platelet count deficiency causes diseases including primary-cord syndrome, idiopathic thrombocytopenic purpura, wilt-aor syndrome, hyperparathyroidism, thrombotic microangiopathy, disseminated intravascular coagulation, heparin-induced thrombocytopenia, von willebrand disease, modified von willebrand disease, thrombocytopenia due to HIV infection, thrombocytopenia due to chronic liver disease, drug-induced thrombocytopenia and/or glantzmann thrombocytopenia, acute radiation disease, bone marrow suppression and/or gastrointestinal tract injury due to various radiation irradiation, bone marrow suppression and/or gastrointestinal tract injury due to tumor radiation therapy, radiation damage to normal tissue cells due to chemotherapy or surgical combination, radiation damage to nuclei and radiation damage, chronic radiation syndrome.

Further, the acute radiation diseases include mild myelogenous acute radiation disease, moderate myelogenous acute radiation disease, severe myelogenous acute radiation disease and intestinal radiation disease.

Further, the platelet deficiency causes diseases and also includes platelet deficiency caused after cancer radiotherapy or chemotherapy.

In some embodiments, the treatment of the disorder resulting from insufficient platelet count generally involves platelet deficiency due to megakaryocyte deficiency or causes of platelet deficiency due to megakaryocyte deficiency are expected. In this case, thrombocytopenia (i.e., an insufficient number of platelets in the present invention) is generally referred to as thrombocytopenia. In some embodiments, the thrombocytopenia may occur for a variety of reasons, including chemotherapy and other treatments with multiple drugs, radiation therapy, surgery, accidental blood loss, and other specific conditions. Typical specific conditions which relate to thrombocytopenia and which can be treated according to the present invention are: aplastic anemia, thrombocytopenia, metastatic tumors leading to thrombocytopenia, systemic lupus erythematosus, splenomegaly, fanconi syndrome, vitamin B12 deficiency, folic acid deficiency, may-Hegglin abnormalities, wiskott-Aldrich syndrome, and paroxysmal nocturnal hemoglobinuria. In addition, certain therapies for AIDS result in thrombocytopenia (e.g., AZT).

In some embodiments, for the case of a predicted megakaryocyte deficiency resulting in a platelet deficiency, the polypeptide or fusion protein of the invention may be administered within days or hours before the condition is expected to occur. In some embodiments, the polypeptides or fusion proteins of the invention may be administered simultaneously with blood or purified platelets in the event of an acute transfusion situation.

In some embodiments, the types of cancer include, but are not limited to, acute lymphoblastic leukemia; acute non-lymphocytic leukemia; adenoma; adrenal cortex cancer; breast cancer, prostate cancer, and colon cancer; enameloblastoma; apud tumor (apudoma); bladder cancer; brain cancer; gill tumour; all forms of lung bronchogenic carcinoma; carcinoid heart disease; malignant carcinoid syndrome; immunoproliferative small lung cell cancer; cementoma; cervical cancer; chondroblastoma; cartilage tumor; chondrosarcoma; a vaginosis tumor; chronic lymphocytic leukemia; chronic myelogenous leukemia; chordoma; craniopharyngeal pipe tumor; cutaneous T cell lymphoma; a vegetative cell tumor; endometrial cancer; esophageal cancer; ewing's sarcoma; fibroids; fibrosarcoma; gallbladder cancer; giant cell tumor; glioma; hairy cell leukemia; hamartoma; neck cancer; liver cancer; histiocytopathy; hodgkin's lymphoma; kaposi's sarcoma; renal cancer; a fatty tumor; liposarcoma; liver cancer; lung cancer (small and non-small cells); malignant peritoneal exudation; malignant pleural effusion; melanoma; a stromal tumor; mesonephroma; mesothelioma; multiple myeloma; myosarcoma; myxoma; myxosarcoma; neuroblastoma; non-Hodgkin's lymphoma; dental tumor; osteoma; osteosarcoma; ovarian cancer; ovarian (germ cell) cancer; pancreatic cancer; papillomas; penile cancer; plasmacytoma; reticuloendotheliosis; retinoblastoma; skin cancer; soft tissue sarcoma; squamous cell carcinoma; stomach cancer; teratoma; testicular cancer; thymoma; thyroid cancer; trophoblastic tumors; uterine cancer; vaginal cancer; vulvar cancer; wilm's tumor.

The invention provides application of the polypeptide and the fusion protein in preparation of products for detecting the TPOR level of an individual.

The present invention provides a product for detecting the level of TPOR in an individual, said product comprising a polypeptide as described above, a fusion protein as described above, and a detectable label linked to the polypeptide as described above, the fusion protein as described above, without affecting the function of the polypeptide or the fusion protein.

Further, the products include reagents, kits, test papers, systems, and devices.

The invention provides the use of the polypeptide as defined above, the fusion protein as defined above for the preparation of a product for maintaining the viability of platelets and/or megakaryocyte-related cells.

Further, the megakaryocyte-related cells include megakaryocyte progenitor cells, primitive megakaryocytes, naive megakaryocytes, and platelets.

Further, the megakaryocyte includes granular megakaryocyte, platelet-producing megakaryocyte, and nukaryocyte.

In some embodiments, the megakaryocyte-associated cells further include megakaryocytes associated with abnormal platelet production, specific examples include micromegakaryocytes, megamononuclear (low nuclear leaf) megakaryocytes, binuclear (low nuclear leaf) megakaryocytes, polynuclear megakaryocytes, vacuolated megakaryocytes, large platelets, megaplatelets, malformed platelets. In some embodiments, the polypeptide or fusion protein is used to maintain the activity of megakaryocytes associated with abnormal thrombopoiesis in order to preserve the corresponding biological material, with a low proportion of megakaryocytes produced in the bone marrow and therefore a lower proportion of abnormal megakaryocytes produced.

The invention also provides a method for restoring or increasing the number of platelets for non-therapeutic purposes in vitro, comprising the step of administering to cells and/or tissues in vitro the polypeptide as described above, the fusion protein as described above, the nucleic acid molecule as described above, the vector as described above, the composition as described above.

The invention has the advantages and beneficial effects that:

The TPOR binding peptide designed by the invention has the functions of stimulating platelet generation, recovering the number of white blood cells, recovering the number of red blood cells and increasing the hemoglobin, has good internal and external activities, has excellent effects on preventing and treating the abnormality caused by radiation irradiation, and has better application potential in treating or preventing diseases caused by insufficient number of platelets.

Drawings

FIG. 1 is a diagram showing the result of SDS-PAGE electrophoresis to detect the purity of an antibody;

FIG. 2 is a graph of ELISA assay results;

FIG. 3 is a graph showing the results of peripheral blood image detection in mice.

Detailed Description

Throughout this disclosure, various publications, patents, and published patent specifications are referenced by identifying citations. All documents cited in this specification are incorporated herein by reference in their entirety. In particular, the teachings or portions of such documents specifically mentioned herein are incorporated by reference.

Unless otherwise defined, all terms used in disclosing the present invention, including technical and scientific terms, have the meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. By way of further guidance, term definitions are included to better understand the teachings of the present invention. Unless otherwise defined, when defining particular terms in connection with a particular aspect or embodiment of the invention, such meaning is intended to apply throughout this specification, i.e., also in the case of other aspects or embodiments of the invention.

Example 1 plasmid construction

1. Experimental method

The TPOR binding peptide sequence of the 2B9 polypeptide is connected with human IgG1Fc through a connector, and then is connected with an expression vector pCDNA3.1 to construct a recombinant expression plasmid pCDNA3.1-2B9. And for pCDNA3.1-2B9. And performing enzyme digestion identification and sequencing confirmation.

2. Experimental results

The sequence of the target gene and amino acid in pCDNA3.1-2B9 obtained after sequencing is shown in Table 1.

TABLE 1

Example 2 purification and detection of expression of 2B9-Fc fusion protein

1. Experimental method

1) Fusion protein expression purification

According to the kit instructions, pCDNA3.1-2B9 was transfected into mammalian cells ExpiCHO using ExpiCHO transfection kit, 125 r/min,37℃and 5% CO 2 cell shaking culture, 8-10 d and cell culture supernatants were collected and purified on ProteinAFF protein columns. Eluting with citric acid buffer of pH3.0, collecting the effluent, neutralizing with 1 mol/L pH8.5TRIS-HCL buffer, dialyzing with 0.01 mol/L pH7.2PBS for 72 h, and filtering with 0.22 μm filter membrane for sterilization. The BCA method detects the concentration of the purified antibody, and SDS-PAGE electrophoresis detects the purity of the antibody.

2) ELISA experiments

The coating solution was diluted to 1. Mu.g/mL of human or murine c-MPL, 100. Mu.L per well was added to the ELISA plate overnight at 4 ℃; after PBST is washed 3 times, 5% milk is blocked, and incubated at 37 ℃ for 1 h; absorbing and discarding the blocking solution, adding the 2B9-Fc fusion protein diluted by the gradient of the blocking solution, and incubating at 37 ℃ for 1 h at an initial concentration of 1 mug/mL; after PBST is washed 3 times, goat anti-human (Fab') 2-HRP secondary antibody is added for reaction at room temperature 45 min; after PBST was washed 3 times, TMB was developed. The absorbance (A450) value at 450 nm was measured after termination of 1 mol/L of sulfuric acid.

2. Experimental results

The results of detecting the purity of the antibody by SDS-PAGE are shown in FIG. 1, and the results show that the 2B9-Fc fusion protein has excellent purification results and can be used for the subsequent experiments. At the same time, ELISA experiments were also performed to detect absorbance at 450 nm, and the results are shown in FIG. 2, which shows that ELISA detection results are excellent.

EXAMPLE 3 Effect of 2B9-Fc treatment administration on peripheral blood images of 6.0Gy gamma-irradiated mice

1. Experimental method

Mouse peripheral blood image detection

Mice were fixed in a custom made mouse irradiation box, and 6.0Gy60Co gamma rays were irradiated systemically at a dose rate of 46.66 cGy/min, the day of irradiation being defined as day 0 of the test. The mice were randomized into solvent control (IR) and 2B9-Fc treated groups of 6 mice each. The 2B9-Fc was diluted to 0.5 mg/mL with physiological saline. Mice were subcutaneously injected with physiological saline or 2B9-Fc, respectively, 2h after irradiation, at a volume of 0.2 mL/mouse, i.e., 100 μg 2B 9-Fc/mouse. The peripheral blood cell content was measured by a fully automatic blood cell analyzer with 10. Mu.L/dose of blood collected from the distal tail vein of the mouse. The blood sampling time is 2 days before irradiation, 1 st, 7 th, 10 th, 14 th, 18 th and 30 th days after irradiation.

2. Experimental results

The peripheral blood leukocyte count was measured by peripheral blood image, and as shown in FIG. 3A, peripheral blood leukocytes of mice were rapidly decreased after whole body irradiation with 6.0Gy gamma rays, the solvent control group was decreased to the minimum value at day 7 after the irradiation, and thereafter slow recovery was started, the 2B9-Fc administration group was restored to the pre-irradiation leukocyte count at day 30, and rapid recovery was started after the minimum value at day 1 after the irradiation, and the pre-irradiation leukocyte count was restored at day 14 after the irradiation, and experiments showed that 2B9-Fc administration could accelerate the recovery of leukocytes.

The peripheral blood cell count was measured by peripheral hemogram, and as shown in FIG. 3B, after 6.0Gy gamma irradiation, the peripheral blood cell count of two groups of mice was progressively decreased, there was no significant difference between groups within 7 days after irradiation, the solvent control group was the lowest 18 days after irradiation, decreased to 37% of the pre-irradiation level, and thereafter gradually recovered. The number of red blood cells on day 18 of the 2B9-Fc administration group was 94% of the pre-irradiation level, and the number of red blood cells on day 10-30 of the post-irradiation period were higher than that of the contemporaneous control group, and the difference from the solvent control group was extremely remarkable or very remarkable.

The number of peripheral blood platelets was measured by peripheral hemogram, and as shown in FIG. 3C, the number of peripheral blood platelets in mice was progressively decreased after whole body irradiation with 6.0Gy gamma rays, and the solvent control group (IR) reached a minimum value of (56.+ -. 16). Times.10 9/L10 days after irradiation, and was gradually recovered. Platelets from mice in the 2B 9-Fc-dosed group reached a minimum of (720.+ -.58). Times.10 9/L on day 7, after which rapid recovery began. The differences between the 2B9-Fc dosed groups compared to the solvent control group were very significant or extremely significant at days 7-30 post-irradiation.

The number of peripheral blood hemoglobin was measured by peripheral hemogram, and as shown in FIG. 3D, the content of peripheral hemoglobin in the 6.0Gy gamma ray irradiated mice was progressively decreased after the irradiation, the solvent control group reached the minimum value of (53.7.+ -. 15.2) g/L18 days after the irradiation, and the 2B9-Fc administration group reached the minimum value of (122.5.+ -. 6.2) g/L10 days after the irradiation. Administration of 2B9-Fc improves hemoglobin reduction and promotes recovery in the mice being treated.

The above description of the embodiments is only for the understanding of the method of the present invention and its core ideas. It should be noted that it will be apparent to those skilled in the art that several improvements and modifications can be made to the present invention without departing from the principle of the invention, and these improvements and modifications will fall within the scope of the claims of the invention.

Claims (10)

1. A polypeptide with therapeutic or preventive function has the amino acid sequence shown in SEQ ID NO. 1.

2. A fusion protein with therapeutic or prophylactic function, which comprises the polypeptide of claim 1, and the sequence of the fusion protein is shown as SEQ ID NO. 7.

3. A nucleic acid molecule which is a nucleotide sequence encoding the polypeptide of claim 1 or the fusion protein of claim 2.

4. A vector comprising the nucleic acid molecule of claim 3.

5. A composition comprising the polypeptide of claim 1, the fusion protein of claim 2, the nucleic acid molecule of claim 3, and/or the vector of claim 4.

6. Use of the polypeptide of claim 1, the fusion protein of claim 2, the nucleic acid molecule of claim 3, the vector of claim 4, or the composition of claim 5 in any of the following: (1) The application of the composition in preparing a pharmaceutical composition for improving the production quantity of blood cells of an individual; (2) The use of a pharmaceutical composition for the treatment or prevention of radiation-induced platelet deficiency; (3) Application in preparing tool medicine for resisting radiation injury research.

7. The use according to claim 6, wherein the radiation-induced platelet count deficiency comprises acute radiation disorder, bone marrow depression caused by various radiation, tumor radiotherapy, chemotherapy or surgery in combination with radiation, nuclear and radiation injury, normal tissue cell radiation injury, chronic radiation syndrome.

8. Use of the polypeptide of claim 1, or the fusion protein of claim 2, in any of the following: (1) use in the preparation of a product for detecting the level of TPOR in an individual; (2) Use in the preparation of a product for maintaining the viability of platelet and/or megakaryocyte-associated cells.

9. A product for detecting the level of TPOR in an individual, the product comprising the polypeptide of claim 1, the fusion protein of claim 2, and a detectable label linked to the polypeptide of claim 1, the fusion protein of claim 2 without affecting the function of the polypeptide or fusion protein.

10. A method of restoring or increasing the number of platelets for non-therapeutic purposes in vitro, comprising the step of administering to cells and/or tissues in vitro the polypeptide of claim 1, the fusion protein of claim 2, the nucleic acid molecule of claim 3, the vector of claim 4, or the composition of claim 5.

CN202410331263.4A 2024-03-22 2024-03-22 TPOR-binding peptides that promote platelet production Active CN117924430B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410331263.4A CN117924430B (en) 2024-03-22 2024-03-22 TPOR-binding peptides that promote platelet production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202410331263.4A CN117924430B (en) 2024-03-22 2024-03-22 TPOR-binding peptides that promote platelet production

Publications (2)

Publication Number Publication Date
CN117924430A CN117924430A (en) 2024-04-26
CN117924430B true CN117924430B (en) 2024-06-28

Family

ID=90766916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202410331263.4A Active CN117924430B (en) 2024-03-22 2024-03-22 TPOR-binding peptides that promote platelet production

Country Status (1)

Country Link
CN (1) CN117924430B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117986346A (en) * 2024-04-07 2024-05-07 中国人民解放军军事科学院军事医学研究院 TPO mimetic peptide and application thereof
CN118043359A (en) * 2021-09-24 2024-05-14 四川三叶草生物制药有限公司 TPO mimetic fusion proteins and methods of use
CN118027155A (en) * 2024-04-15 2024-05-14 中国人民解放军军事科学院军事医学研究院 TPOR binding peptide and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU749175B2 (en) * 1994-01-03 2002-06-20 Genentech Inc. Thrombopoietin
EP1471933A1 (en) * 2002-02-07 2004-11-03 Delta Biotechnology Limited Albumin-fused anti-angiogenesis peptides
US9850296B2 (en) * 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN102309743A (en) * 2011-08-03 2012-01-11 中国人民解放军军事医学科学院放射与辐射医学研究所 New purpose of recombinant human thrombopoietin (rhTPO)
KR101551306B1 (en) * 2015-03-23 2015-09-09 아주대학교산학협력단 Neuropilin-1 specific binding peptides and its fusion protein, and use thereof
CN114028387B (en) * 2022-01-10 2022-04-08 中国人民解放军军事科学院军事医学研究院 Application of Brusatol in preparation of anti-radiation injury medicine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118043359A (en) * 2021-09-24 2024-05-14 四川三叶草生物制药有限公司 TPO mimetic fusion proteins and methods of use
CN117986346A (en) * 2024-04-07 2024-05-07 中国人民解放军军事科学院军事医学研究院 TPO mimetic peptide and application thereof
CN118027155A (en) * 2024-04-15 2024-05-14 中国人民解放军军事科学院军事医学研究院 TPOR binding peptide and application thereof

Also Published As

Publication number Publication date
CN117924430A (en) 2024-04-26

Similar Documents

Publication Publication Date Title
US11717559B2 (en) 2023-08-08 Interleukin 15 protein complex and use thereof
JP6073409B2 (en) 2017-02-01 Use of IL-1 inhibitors and TNF antagonists partially combined with recombinant erythropoietin for the treatment of anemia
DE69934425T2 (en) 2007-09-27 THROMBOPOIETIN SUBSTITUTE
US10206980B2 (en) 2019-02-19 IL-15 heterodimeric protein and uses thereof
ES2314999T3 (en) 2009-03-16 MOTHER CELL FACTOR.
JP6888221B2 (en) 2021-06-16 How to use soluble CD24 for the treatment of rheumatoid arthritis
CN105924516A (en) 2016-09-07 Variant Activin Receptor Polypeptides And Uses Thereof
CN102816242A (en) 2012-12-12 Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
CA2958906C (en) 2021-05-04 Disintegrin variants and pharmaceutical uses thereof
JP2022512541A (en) 2022-02-07 Combination therapy including PD-1 chimeric protein
WO2021190551A1 (en) 2021-09-30 Chimeric antigen receptor that binds to cd19 and use thereof
JP2019516363A (en) 2019-06-20 Fusion protein containing CCL3 mutant and use thereof
WO1992001002A1 (en) 1992-01-23 Tumor necrosis factor activity inhibitor and production thereof
CN117924430B (en) 2024-06-28 TPOR-binding peptides that promote platelet production
JP2022503621A (en) 2022-01-12 Combination therapy with TIM-3 chimeric proteins
CN113329752A (en) 2021-08-31 Combination therapy for the treatment of myeloproliferative tumors using diphtheria toxin-human interleukin-3 conjugates in combination with other agents
EP4386011A1 (en) 2024-06-19 Gpc3-targeted antibody interferon alpha fusion protein and use thereof
WO2023011662A1 (en) 2023-02-09 Anti-her-2 antibody-granulocyte regulatory factor fusion protein, preparation method therefor and application thereof
Antisense 2004 Antibodies to specific regions of cyclosporine related compounds
NZ795260A (en) 2022-12-23 Manufacturing Optimization of GL-2045, a Multimerizing Stradomer

Legal Events

Date Code Title Description
2024-04-26 PB01 Publication
2024-04-26 PB01 Publication
2024-05-14 SE01 Entry into force of request for substantive examination
2024-05-14 SE01 Entry into force of request for substantive examination
2024-06-28 GR01 Patent grant
2024-06-28 GR01 Patent grant